Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|December 20, 2021

Understanding the Clinical Burden of Prostate Cancer

Author(s)John L. Fox, MD, MHA, Maria Lopes, MD, MS, Bhavesh Shah, RPh, BCOP

Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.

Episodes in this series

Expert on Prostate Cancer

EP. 1 Understanding the Clinical Burden of Prostate Cancer

Expert on Prostate cancer

EP. 2 Prostate Cancer’s Impact on Economy and Life

Expert on prostate cancer

EP. 3 Correlation Between Prostate Cancer and Cardiovascular Disease

Expert on prostate cancer

EP. 4 An Overview of the Prostate Cancer Treatment Landscape

Expert on prostate cancer

EP. 5 CVD Risk Associated With ADT in Prostate Cancer

Expert on prostate cancer

EP. 6 Prostate Cancer: Identifying Patients at Risk for CVD

Expert on prostate cancer

EP. 7 Prostate Cancer and CVD: Professional Society Guidelines

Expert on prostate cancer

EP. 8 Impact of CVD Risk on Cost of Care in Prostate Cancer

Expert on prostate cancer

EP. 9 CVD in Prostate Cancer: Risk-Bearing Practices and Alternative Payment Models

Expert on prostate cancer

EP. 10 Factors in Evaluating Therapy for Prostate Cancer

Expert on prostate cancer

EP. 11 What Evidence Is Needed to Further Define CVD Risk in Prostate Cancer?

Expert on prostate cancer

EP. 12 CVD Risk in Prostate Cancer: Quality Measures and Coverage Policy

Expert on prostate cancer

EP. 13 Multidisciplinary Care in Prostate Cancer and CVD Management

Expert on prostate cancer

EP. 14 CVD Risk in Prostate Cancer: Future Directions in Care

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Mary-Ellen Taplin, MD, FASCO | Image Credit: Dana-Farber Cancer Institute

Apalutamide Plus ADT Improves Outcomes in High-Risk Prostate Cancer: Mary-Ellen Taplin, MD

ByElla Hohmann, MS,Mary-Ellen Taplin, MD, FASCO

June 8th 2026

Dual-Target ADC Shows 15-Month Progression-Free Survival in Prostate Cancer: Tanya Dorff, MD

ByElla Hohmann, MS,Tanya Barauskas Dorff, MD, FASCO

May 31st 2026

ARACOG Trial Links Enzalutamide to Greater Cognitive Decline Compared With Darolutamide: Alicia Morgans, MD, MPH

ByElla Hohmann, MS,Alicia Morgans, MD, MPH

May 30th 2026

Daniel George, MD | Image: Duke Health

For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials

March 3rd 2026

prostate cancer | Image: Dr Microbe Adobe

Radiopharmaceutical Medicare Use Jumps: ASTRO Abstracts Outline Delivery Models

February 20th 2026

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA

Early Data Show Revumenib Offers Maintenance Option in AML Following SCT